Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

10.1K
Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
10.1K
Covalently Linked Protein Regulators02:04

Covalently Linked Protein Regulators

8.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
8.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

8.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.6K
The Proteasome01:13

The Proteasome

1.6K
Eukaryotic cells can degrade proteins through several pathways. One of the most important among these is the ubiquitin-proteasome pathway. It helps the cell eliminate the misfolded, damaged, or unwarranted cytoplasmic proteins in a highly specific manner.
In this pathway, the target proteins are first tagged with small proteins called ubiquitin. This involves participation of a series of enzymes including— E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzyme), and E3...
1.6K
Protein Kinases and Phosphatases02:54

Protein Kinases and Phosphatases

15.0K
Proteins undergo chemical modifications that trigger changes in the charge, structure, and conformation of the proteins. Phosphorylation, acetylation, glycosylation, nitrosylation, ubiquitination, lipidation, methylation, and proteolysis are various protein modifications that regulate protein activity. Such modifications are usually enzyme-driven.
Protein kinases
Many proteins in the cell are regulated by phosphorylation, the addition of a phosphate group. A family of enzymes called kinases...
15.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

SIRT2-mediated deacetylation activates USP22 catalytic function for PD-L1 protein stabilization and tumor immune escape.

The Journal of clinical investigation·2026
Same author

A frame of wideband wireless signal recognition and parameter extraction based on semantic segmentation.

PloS one·2026
Same author

Covalent JAK3 inhibitors based on 2-arylamino and 7H-pyrrolo[2,3-d]pyrimidine scaffold: design, synthesis, and biological evaluation for the potential treatment of bortezomib-resistant multiple myeloma.

European journal of medicinal chemistry·2026
Same author

Bone matrix proteins: regulators of skeletal remodeling and repair.

Journal of bone and mineral metabolism·2026
Same author

Design and Synthesis of KRAS<sup>G12C</sup> Inhibitors for Antitumor Evaluation Harboring Combination Therapy with Nrf2, PARP-7, and Pan-USP Inhibitors to Alleviate Drug Resistance Synergistically.

Journal of medicinal chemistry·2026
Same author

Sb<sub>70</sub>Ag<sub>30</sub> Alloy Cathode: Lithiation-Induced Li<sub>2</sub>AgSb/Li<sub>3</sub>Sb Interpenetrating Network Enables High Energy/Power Density Liquid Metal Batteries.

Small (Weinheim an der Bergstrasse, Germany)·2025

Related Experiment Video

Updated: Jan 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K

Spotlight on USP30: structure, function, disease and target inhibition.

Jiapeng Du1, Yiyang Gao1, Guoqing Xue1

  • 1College of Pharmacy, Dalian Medical University, Dalian, China.

Frontiers in Pharmacology
|September 8, 2025
PubMed
Summary

Ubiquitin-specific protease 30 (USP30) is vital for cellular health and implicated in cancer and neurodegenerative diseases. Inhibiting USP30 shows therapeutic promise for these conditions.

Keywords:
USP30diseasesignaling pathwaystructuretarget inhibition

More Related Videos

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay
07:05

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Published on: September 27, 2024

940
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

807

Related Experiment Videos

Last Updated: Jan 18, 2026

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors
08:45

Assessing Cellular Target Engagement by SHP2 PTPN11 Phosphatase Inhibitors

Published on: July 17, 2020

6.6K
Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay
07:05

Measuring Enzymatic Activity of Neurodevelopmental Disorder-Associated Deubiquitylating Enzymes via an In Vitro Ubiquitin Chain Cleavage Assay

Published on: September 27, 2024

940
Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases
06:56

Author Spotlight: Developing Tools to Tune the Activity of Tyrosine Phosphatases

Published on: September 6, 2024

807

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Cell Biology

Background:

  • Ubiquitin-specific protease 30 (USP30) is a deubiquitinating enzyme critical for maintaining cellular homeostasis.
  • USP30 regulates key cellular processes including mitochondrial quality control and autophagy.
  • Dysregulation of USP30 is linked to various pathologies, notably cancers and neurodegenerative disorders.

Purpose of the Study:

  • To provide a comprehensive review of USP30, encompassing its structure, function, and disease associations.
  • To explore the therapeutic potential of USP30 inhibition in malignancies and neurodegenerative diseases.
  • To discuss current controversies and future directions in USP30 research.

Main Methods:

  • Literature review of studies on USP30.
  • Analysis of USP30's role in cellular mechanisms like autophagy and metabolic reprogramming.
  • Examination of preclinical data on USP30 inhibitors (e.g., S3, MF-094, FT3967385).

Main Results:

  • USP30 influences mitochondrial autophagy, oncoprotein stability (Snail, c-Myc), and metabolic reprogramming.
  • USP30 inhibition demonstrates potential in reversing tumor malignancy and offering neuroprotection.
  • Pharmacological inhibition reactivates mitophagy and enhances ubiquitination, showing promise in preclinical models.

Conclusions:

  • USP30 is a significant target for therapeutic intervention in cancer and neurodegenerative diseases.
  • Targeted therapies against USP30 hold promise but require further investigation.
  • Continued research into USP30 mechanisms will advance understanding and treatment strategies.